483
Balamurali K. Ambati , M.D., Ph.D.FDA 483 - Balamurali K. Ambati , M.D., Ph.D. - April 04, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Balamurali K. Ambati, M.D., Ph.D, MBA, Clinical Investigator in Eugene, OR, revealed a critical failure to submit an Investigational New Drug (IND) application. This omission occurred prior to conducting a clinical investigation involving an unapproved combination product. The study, which began in April 2017 and is ongoing, proceeded without the required FDA authorization, posing a significant regulatory non-compliance issue.
Open in Dashboard
ID · 5e6088ad-c61f-4254-805a-3c4412368071